Merck Gets Second Chance On Dual PPAR: Will Co-Develop Bristol's Muraglitazar

Bristol cites shift in focus to specialty care as one reason to out-license the product. Merck will pay $100 mil. upfront and $275 mil. in milestone payments for rights to the dual PPAR agonist and a back-up compound in Phase II.